State Street Corp Sells 655,041 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)

State Street Corp cut its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 8.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,013,083 shares of the company’s stock after selling 655,041 shares during the quarter. State Street Corp owned 3.34% of Allogene Therapeutics worth $19,637,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in ALLO. Primecap Management Co. CA raised its holdings in Allogene Therapeutics by 4.1% in the 2nd quarter. Primecap Management Co. CA now owns 5,670,226 shares of the company’s stock valued at $13,212,000 after buying an additional 221,840 shares during the last quarter. Perceptive Advisors LLC bought a new position in shares of Allogene Therapeutics during the second quarter valued at $6,349,000. Dimensional Fund Advisors LP lifted its holdings in shares of Allogene Therapeutics by 24.8% during the second quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock worth $5,944,000 after purchasing an additional 507,021 shares during the period. Lynx1 Capital Management LP acquired a new position in shares of Allogene Therapeutics during the second quarter worth $5,192,000. Finally, Renaissance Technologies LLC grew its stake in shares of Allogene Therapeutics by 340.4% in the second quarter. Renaissance Technologies LLC now owns 1,747,955 shares of the company’s stock worth $4,073,000 after purchasing an additional 1,351,055 shares during the last quarter. 83.63% of the stock is owned by institutional investors and hedge funds.

Allogene Therapeutics Stock Up 4.3 %

Shares of NASDAQ ALLO opened at $1.95 on Tuesday. The firm has a market cap of $408.86 million, a PE ratio of -1.25 and a beta of 0.83. The company’s fifty day simple moving average is $2.48 and its 200 day simple moving average is $2.56. Allogene Therapeutics, Inc. has a 12-month low of $1.78 and a 12-month high of $5.78.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. William Blair reaffirmed an “outperform” rating on shares of Allogene Therapeutics in a report on Thursday, November 14th. Piper Sandler cut their price objective on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Finally, HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Allogene Therapeutics in a research report on Friday, November 8th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, Allogene Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $9.73.

Allogene Therapeutics Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).